Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCSF in ALS
NCT01825551Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2012
- Primary completion
- Nov 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing GCSF with Placebo (2 arms). Primary endpoint: Patient's function at 1 year. Started Nov 2012; status: completed.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01825551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01825551.